Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XOMA 358 in Post-Bariatric Hypoglycemia
NCT02772718Phase 2Completed
- Sponsor
- XOMA
- Start
- Apr 2016
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ersodetug in hypoglycemia (2 arms), sponsored by XOMA. Primary endpoints: Incidence of treatment-emergent adverse events at 42 days, Change from baseline in glucose levels at 22 days and 3 more. Started Apr 2016; status: completed.
02
Drugs
ersodetug
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT02772718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772718.